The Latest Breaking News from LLY

Despite the cooling inflation, the Fed is not expected to cut rates in 2023 as it is committed to achieving its 2% inflation target. Continued rate hikes, albeit at a lower rate, could potentially push the economy into a recession this year. Amid lingering recession fears, it could be wise…

Pharma sector usually performs relatively well amid market turmoil due to the inelastic demand for its offerings. Moreover, increased technological advancements should boost the industry’s growth. Hence, pharma stocks Eli Lilly (LLY), AstraZeneca (AZN), Zoetis (ZTS), and Teva Pharmaceutical (TEVA) might be worth buying in 2023. Read more.

While moderation of the inflation rate is December has triggered a bear market rally, the stock market is unlikely to stabilize in the near term because of the likelihood of further interest rate hikes. Hence, shares of fundamentally strong and growing businesses with a track record of increasing dividend payouts,…

With the Fed signaling to continue raising interest rates throughout this year, the probability of the economy tipping into a recession is increasing. Amid the macroeconomic unrest, fundamentally sound large-cap stocks UnitedHealth Group (UNH), Walmart (WMT), and Eli Lilly (LLY) might be safe investments this year. Read on….

The Fed’s aggressive stance on inflation has weighed heavily on the stock market this year. As large-cap stocks usually can weather challenging economic conditions, sound large-cap stocks Eli Lilly (LLY), Agilent Technologies (A), and Fortinet (FTNT) might be wise additions to your portfolio. Keep reading.

With slower but surer interest rate hikes expected to put further pressure on the compressed margins of most companies and enhance the odds of an economic slowdown, the market is unlikely to stabilize anytime soon. Hence, it could be wise to load up on steady stocks, Microsoft (MSFT) and Eli…

The pharmaceutical industry is rapidly evolving to meet today’s health challenges. The pharmaceutical industry's long-term prospects look bright with a globally aging population set to increase healthcare expenditure. Moreover, given the industry’s ability to stay resilient amid economic headwinds, it could be wise to invest in fundamentally strong pharmaceutical stocks…

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application. 

Although the stock market has been under pressure this year due to macroeconomic headwinds, the pharmaceutical industry continues to garner investor attention as it enjoys inelastic demand for its products regardless of economic conditions. Thus, fundamentally-sound pharma stocks Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) could be worth your attention…

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 21 strange trades.

Someone with a lot of money to spend has taken a bullish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.